Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) FCF Margin (2020 - 2025)

Historic FCF Margin for Harmony Biosciences Holdings (HRMY) over the last 6 years, with Q3 2025 value amounting to 45.38%.

  • Harmony Biosciences Holdings' FCF Margin rose 74800.0% to 45.38% in Q3 2025 from the same period last year, while for Sep 2025 it was 35.95%, marking a year-over-year increase of 36600.0%. This contributed to the annual value of 30.59% for FY2024, which is 70500.0% down from last year.
  • Per Harmony Biosciences Holdings' latest filing, its FCF Margin stood at 45.38% for Q3 2025, which was up 74800.0% from 39.56% recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' FCF Margin ranged from a high of 47.03% in Q3 2022 and a low of 18.33% during Q1 2025
  • For the 5-year period, Harmony Biosciences Holdings' FCF Margin averaged around 33.05%, with its median value being 35.73% (2023).
  • In the last 5 years, Harmony Biosciences Holdings' FCF Margin skyrocketed by 1555800bps in 2021 and then crashed by -203600bps in 2022.
  • Quarter analysis of 5 years shows Harmony Biosciences Holdings' FCF Margin stood at 41.15% in 2021, then plummeted by -49bps to 20.79% in 2022, then skyrocketed by 119bps to 45.46% in 2023, then decreased by -18bps to 37.29% in 2024, then rose by 22bps to 45.38% in 2025.
  • Its FCF Margin was 45.38% in Q3 2025, compared to 39.56% in Q2 2025 and 18.33% in Q1 2025.